Biomea Fusion rises on FDA clearance to start trial for leukemia treatment

Biomea Fusion

01/05/2023 16:38

** Shares of drug developer Biomea Fusion Inc  BMEA.O  rise
5.7% to $31.14
    ** Co says FDA has cleared co's application to begin a early
stage trial of BMF-500 
    ** Early-stage trial of BMF-500 will examine its safety and
efficacy in patients with types of leukemia
    ** Stock up ~270% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))